{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:16:50Z","timestamp":1790482610084,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Nobelpharma Co., Ltd."},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP17pc010101"],"award-info":[{"award-number":["JP17pc010101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Kidney transplantation (KT) has dramatically improved the quality of life of patients with end-stage kidney disease. However, the incidence of opportunistic infections has also increased because of immunosuppression. A common infection after KT is cytomegalovirus (CMV). In KT recipients, we assessed the efficacy and safety of fiztasovimab (NPC-21), an anti-CMV monoclonal antibody.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of NPC-21 for KT recipients with CMV donor-positive (D<jats:sup>+<\/jats:sup>)\/recipient-negative (R<jats:sup>\u2212<\/jats:sup>) serostatus. Patients were randomly assigned to receive monthly 6 or 12\u2009mg\/kg NPC-21, or placebo, in a 4:1:4 ratio. The primary efficacy endpoint was CMV infection by week 16.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Eighty-seven KT recipients were randomized; 38, 11, and 38 received 6\u2009mg\/kg of NPC-21, 12\u2009mg\/kg of NPC-21, or placebo, respectively. CMV infections occurred in 29 of 38 (76.3%), 9 of 11 (81.8%), and 26 of 38 (68.4%) patients in the 6\u2009mg\/kg NPC-21, 12\u2009mg\/kg NPC-21, and placebo groups, respectively, with no statistically significant differences. CMV disease occurred in 2 of 49 (4.1%) versus 5 of 38 (13.2%) patients in the 6 and 12\u2009mg\/kg combined NPC-21 group versus the placebo group. The absolute difference (95% confidence interval) was \u22129.1 (\u221223.9 to 2.8). No significant adverse events were observed after NPC-21 administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>NPC-21 was safe, but no significant efficacy difference was found between NPC-21 and placebo. Severe CMV infection was less likely in the NPC-21 group versus the placebo group. Further studies are needed to elucidate the role of NPC-21 in the prevention of CMV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005260","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:00:25Z","timestamp":1741770025000},"page":"985-993","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21)"],"prefix":"10.1097","volume":"109","author":[{"given":"Naotsugu","family":"Ichimaru","sequence":"first","affiliation":[{"name":"Department of Urology, Kinki Central Hospital, Hyogo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Natori","sequence":"additional","affiliation":[{"name":"Miami Transplant Institute, Jackson Health System, Miami, FL."},{"name":"Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita R.","family":"Alloway","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia E.","family":"Castillo Almeida","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Research and Development Division, Nobelpharma Co Ltd, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Egawa","sequence":"additional","affiliation":[{"name":"Hamamatsu Rosai Hospital, Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LionHeart21 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"key":"R1-20250714","article-title":"Global Kidney Health Atlas, 3rd ed., 2023."},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/ndt\/gfab232","article-title":"Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review.","volume":"36","author":"Wang","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R3-20250714","article-title":"2023 USRDS annual data report: epidemiology of kidney disease in the United States."},{"key":"R4-20250714","article-title":"Based on Organ Procurement and Transplantation Network data as of January 18, 2024."},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eimc.2009.07.008","article-title":"Direct and indirect effects of cytomegalovirus: can we prevent them?","volume":"28","author":"Razonable","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R7-20250714","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"R8-20250714","article-title":"Valcyte (valganciclovir): US prescribing information."},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial.","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"R10-20250714","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease.","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"e0285672","DOI":"10.1371\/journal.pone.0285672","article-title":"A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B.","volume":"18","author":"Okamoto","year":"2023","journal-title":"PLoS One"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/cpdd.1065","article-title":"Pharmacokinetics, safety, and tolerability of NPC-21, an anti-cytomegalovirus monoclonal antibody, in healthy Japanese and White adult men: a randomized, placebo-controlled, first-in-human phase 1 study.","volume":"11","author":"Furihata","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R17-20250714","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R18-20250714","doi-asserted-by":"crossref","first-page":"e01794","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients.","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"R20-20250714","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial.","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T19:00:18Z","timestamp":1752519618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005260","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]}}}